Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas

作者：Rahman Md Atiqur; Salajegheh Ali; Smith Robert Anthony; Lam Alfred King yin^*

来源：Experimental and Molecular Pathology, 2015, 99(3): 492-497.

DOI：10.1016/j.yexmp.2015.09.006

• Thyroid carcinoma
• BRAF
• cell signalling pathway
• ERK
• AKT

Background and objectives. BRAF is an oncogene which involves in pathogenesis of many thyroid carcinomas. The aim of our study was to investigate whether the downstream signalling pathway of BRAF and AKT kinase signalling pathways were active in BRAFV600E mutated thyroid carcinoma cells. Methods. Five thyroid (papillary and undifferentiated) carcinoma cell lines and one non-cancer thyroid cell line were screened for their BRAFV600E mutation status by immunofluorescent staining and Western blot. BRAF V600E mutated thyroid carcinoma cell lines were used to test the activation status of both ERK and AKT kinase proteins through immunofluorescent studies and Western blots. Results. Expressions of BRAFV600E mutated protein were confirmed in four thyroid (papillary and undifferentiated) carcinoma cell lines. In these cell lines, both active ERK and active AKT kinase proteins were found in BRAFV600E mutated thyroid carcinoma cells by immunofluorescent staining and Western blots experiments. Conclusions. In BRAFV600E mutated thyroid carcinomas, active ERK and active AKT kinase proteins were noted. They are able to stimulate multiple downstream signalling pathways which ultimately result in increased proliferation and survival activities for cancer cells. Therefore, consideration needs to put on multiple targets when deciding molecular target therapies for patients with BRAF V600E mutated thyroid carcinoma.

• 出版日期2015-12